PerkinElmer acquires Horizon, gets EUA for sample pooling
February 2021—PerkinElmer and Horizon Discovery have reached an agreement in which PerkinElmer will acquire Horizon for about $383 million.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Bilirubin calibrator, standard kits
February 2021—Verichem Laboratories released a liquid-stable, protein-based BR2 Bilirubin Calibrator designed for the calibration of Advanced Instruments’ Advanced BR2 Bilirubin Stat Analyzer. The product has an open-vial stability claim of five days and an unopened shelf-life claim of 14 months at 2° to 8°C. The bilirubin calibrator is packaged in amber serum vials with rubber-lined closures and contains 5.0 mL of standard material, with two vials per kit.
Reduced TAT for Vivalytic SARS-CoV-2 positive samples
February 2021—Randox announced that its improved software for the Vivalytic analysis device enables its CE-marked Vivalytic SARS-CoV-2 rapid coronavirus test to deliver results for positive samples in less than 30 minutes.
Sysmex adds CellaVision DC-1 to portfolio
February 2021—Sysmex America has added the FDA 510(k)-cleared CellaVision DC-1 to its portfolio of CellaVision products for low-volume hematology labs.
TTF1, napsin A tests for lung cancer diagnostics
February 2021—Novodiax launched two rapid IhcDirect antibody assays, TTF1 and napsin A, for in vitro diagnostic use.
FDA authorizes OTC at-home test for COVID-19
January 2021—The FDA issued an emergency use authorization for the first over-the-counter, at-home diagnostic test for COVID-19. The Ellume COVID-19 Home Test is a rapid, lateral flow antigen test that detects fragments of proteins of the SARS-CoV-2 virus using a mid-turbinate nasal swab sample from any person two years of age or older. The Ellume home test correctly identified 96 percent of positive samples and 100 percent of negative samples in people who had symptoms. In people without symptoms, the test correctly identified 91 percent of positive samples and 96 percent of negative samples. The home test uses an analyzer that connects with a software application on a smartphone to help users perform the test and interpret results. Results are delivered in as little as 20 minutes via a person’s smartphone. “By authorizing a test for over-the-counter use, the FDA allows it to be sold in places like drug stores, where a patient can buy it, swab their nose, run the test, and find out their results in as little as 20 minutes,” FDA commissioner Stephen M. Hahn, MD, said in a statement released by the agency. “As we continue to authorize additional tests for home use, we are helping expand Americans’ access to testing, reducing the burden on laboratories and test supplies, and giving Americans more testing options from the comfort and safety of their own homes.”
Verichem Labs offers data reduction services
January 2021—Verichem Laboratories is offering its customers free access to the company’s online, web-based data reduction services. Designed for use with Verichem’s products, the service supports the necessary statistics required within the clinical laboratory to satisfy current CLIA and CAP requirements for the calibration verification of clinical assays.
Randox multiplex controls for respiratory disease
January 2021—Randox Laboratories has unveiled its Qnostics Multiplex Respiratory Pathogen Controls for respiratory diseases, including for SARS-CoV-2, influenza A and B, and respiratory syncytial virus. The RTX controls are used to monitor the full testing process, from extraction to amplification and detection, and are compatible with a majority of commercial and in-house assays.
Siemens test measures neutralizing antibodies
January 2020—Siemens Healthineers’ SARS-CoV-2 IgG Antibody Test has proven to measure neutralizing antibodies, the company announced. The test reports quantitative results measuring the amount of neutralizing antibodies present in a patient’s blood sample.
BD FacsLyric 510(k) cleared with FacsDuet sample prep system
January 2021—BD received FDA 510(k) clearance for the BD FacsLyric flow cytometer integrated with the BD FacsDuet sample preparation system. Physical integration between the two instruments allows technicians to load samples and reagents onto the BD FacsDuet and obtain results once the samples are acquired and analyzed on the BD FacsLyric. Data integration using the BD FacsLink middleware solution offers bidirectional communication between the instruments and connectivity with laboratory information systems.